Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compound Phellinus igniarius decoction for radiation pneumonitis
NCT06861179Phase 1Completed
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Mar 2023
- Primary completion
- Dec 2024
- Modality
- Botanical Extract
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of compound Phellinus igniarius decoction in radiation pneumonitis (RP), sponsored by Zhejiang Cancer Hospital. Primary endpoints: Inflammatory factors in blood samples and Tumor markers in blood samples. Started Mar 2023; status: completed.
02
Drugs
compound Phellinus igniarius decoction
03
Conditions
radiation pneumonitis (RP)
Beyond the preview
Go deeper on NCT06861179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06861179.